Abstract
When a human myeloid cell line, U937, was incubated with etoposide (10 micrograms/mL), morphologically apoptotic cells first appeared at 3 hr and increased with time to 50% at 6 hr. Pretreatment of U937 cells for 30 min with a potent tyrosine kinase inhibitor, herbimycin A (10 microM), significantly suppressed the appearance of apoptotic morphological changes. Concomitantly, herbimycin A pretreatment prevented both high molecular weight and internucleosomal DNA fragmentation induced by etoposide. Two major bands at 30 and 66 kDa with enhanced tyrosine phosphorylation inhibited by herbimycin A were detectable after 30 min of incubation with etoposide. In addition, herbimycin A prevented etoposide-induced NF-kappa B activation. The expressions of Bcl-2 and Bax, on the other hand, were not affected by herbimycin A pretreatment. Herbimycin A was also found to inhibit 1-beta-D-arabinofuranosylcytosine-induced apoptotic changes and NF-kappa B activation. These results suggest that activation of tyrosine kinase(s) may play an important role in apoptotic processes induced by a variety of anti-cancer drugs.
References
Jul 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·J RenartG R Stark
Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·F M UckunG L Schieven
Jul 27, 1992·FEBS Letters·S Sen, M D'Incalci
Jan 1, 1991·Methods in Enzymology·Y Uehara, H Fukazawa
Jan 1, 1991·Molecular and Cellular Biology·H P HohmannA P van Loon
Apr 1, 1991·Molecular and Cellular Biology·Y C LiB R Franza
Apr 12, 1990·Nature·S Ghosh, D Baltimore
Jun 1, 1989·Molecular and Cellular Biology·F Shirakawa, S B Mizel
Jun 23, 1988·Nature·K Leung, G J Nabel
Jul 17, 1995·Biochemical and Biophysical Research Communications·L JiY Hirabayashi
Sep 11, 1995·FEBS Letters·T NishiyaY Nomura
Sep 1, 1995·Leukemia Research·K KuwakadoY Wakazono
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·S HaldarC M Croce
May 15, 1995·FEBS Letters·A KataokaK Furusho
Nov 16, 1994·Biochemical Pharmacology·R BesshoR Nishikomori
Jul 15, 1994·Biochemical and Biophysical Research Communications·E LeeK Kariya
Aug 29, 1994·FEBS Letters·H AlbrechtC V Jongeneel
Dec 3, 1993·Cell·C AbbadieP J Enrietto
Dec 15, 1993·Biochemical and Biophysical Research Communications·E SikoraC Franceschi
Jan 1, 1994·Experimental Cell Research·K MatsubaraH Mikawa
Aug 27, 1993·Cell·Z N OltvaiS J Korsmeyer
Jan 1, 1993·International Review of Cytology·M GrilliM J Lenardo
Dec 1, 1995·The Journal of Cell Biology·K I LinR R Ratan
Dec 15, 1995·The Biochemical Journal·A F SlaterS Orrenius
Nov 1, 1996·Science·A A Beg, D Baltimore
Nov 1, 1996·Science·C Y WangA S Baldwin
Oct 1, 1996·Journal of Leukocyte Biology·K E SchlottmannK M Coggeshall
Nov 1, 1996·Biochemical Society Transactions·S OrreniusA F Slater
Citations
Oct 30, 1999·European Journal of Immunology·H MühlJ Pfeilschifter
Sep 29, 2000·Biochemical Pharmacology·V BoursM P Merville
Sep 29, 2000·Biochemical Pharmacology·B B Aggarwal
Aug 19, 2000·Transplantation·S KeshavjeeM Liu
Nov 30, 2006·Neoplasia : an International Journal for Oncology Research·Michael B ArmstrongValerie P Castle
Apr 30, 2003·Environmental and Molecular Mutagenesis·Sophie MeintièresDaniel Marzin
Jul 12, 2003·Leukemia & Lymphoma·Anas YounesBharat B Aggarwal
Dec 22, 1999·Oncogene·M Barkett, T D Gilmore
Oct 19, 2006·British Journal of Cancer·I FabianI Shalit
Sep 19, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Solène GrazideJean-Pierre Jaffrézou
Mar 13, 2001·Oncogene·A ArltH Schäfer
May 27, 2006·Biochemical Pharmacology·Marie-Berthe MaesIngrid De Meester